The market seems to like the recent results and moves to rationalize their onshore pathology assets. Management making some good moves and a solid program of growth in the pipeline. Hope this performs as well as RHC into the future. At this stage I cannot see why it wont.
The market seems to like the recent results and moves to...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)